Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance

BACKGROUND & AIMS: The high costs of direct-acting antiviral (DAA) agents to treat chronic hepatitis C virus (HCV) infection have resulted in denials of treatment, but it is not clear whether patients’ access to these therapies differs with their type of insurance. METHODS: We conducted a prospe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Gastroenterol Hepatol
Main Authors: Re, Vincent Lo, Gowda, Charitha, Urick, Paul N., Halladay, Joshua T., Binkley, Amanda, Carbonari, Dena M., Battista, Kathryn, Peleckis, Cassandra, Gilmore, Jody, Roy, Jason A., Doshi, Jalpa A., Reese, Peter P., Reddy, K. Rajender, Kostman, Jay R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912853/
https://ncbi.nlm.nih.gov/pubmed/27062903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2016.03.040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados